Prescription medicine
Levamlodipine Brand names: Conjupri
Levamlodipine (Conjupri) is a prescription medicine with an FDA approval on record since 2019. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the levamlodipine FDA label on DailyMed (effective December 11, 2024, CSPC Ouyi Pharmaceutical Co. Ltd); the NDA 212895 record on Drugs@FDA; every levamlodipine label on DailyMed.
Highlights of the record
FDA label of December 11, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageCONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure.
Forms and strengths
- 2.5 mg
- 5 mg
Tablet.
On the market
- Earliest approval on file
- December 19, 2019 Conjupri, Cspc Ouyi; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 122 through July 30, 2026
What is levamlodipine used for?
From the label: indications and usageCONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension CONJUPRI ® is indicated for the treatment of hypertension in adults and patients 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. […]
Conditions named in the indications of levamlodipine's FDA labels, with every medicine labeled for each:
Source: FDA drug label (Conjupri), CSPC Ouyi Pharmaceutical Co. Ltd, effective December 11, 2024 (SPL set c3cca66e-348a-43e8-8f96-e995104dae3d), via openFDA; the full label on DailyMed
Is there a generic for levamlodipine (Conjupri)?
No generic levamlodipine is approved (Drugs@FDA, October 8, 2026).
- 2019 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the levamlodipine label say about other medicines?
The levamlodipine label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amlodipine | contraindications | CONTRAINDICATIONS Levamlodipine is contraindicated in patients with known sensitivity to amlodipine. |
| Cyclosporine | drug interactions | Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. |
| Sildenafil | drug interactions | Sildenafil Monitor for hypotension when sildenafil is co-administered with amlodipine [see Clinical Pharmacology ( 12.2 )]. |
| Simvastatin | drug interactions | Amlodipine on Other Drugs Simvastatin Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. |
| Tacrolimus | drug interactions | Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. |
Source: FDA drug label (Conjupri), CSPC Ouyi Pharmaceutical Co. Ltd, effective December 11, 2024 (SPL set c3cca66e-348a-43e8-8f96-e995104dae3d), via openFDA; the full label on DailyMed
What do FAERS reports show for levamlodipine?
The FDA Adverse Event Reporting System holds 122 reports that list levamlodipine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 13 are coded as a death and 73 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as levamlodipine?
72 other medicines are given the same way (oral) and in the same FDA class as levamlodipine or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Metoprolol | High blood pressure | 64 labelers | $0.085 per tablet 100 mg tablet | A presentation being discontinued |
| Diltiazem | High blood pressure | 42 labelers | $0.144 per capsule 24h ER(cd) 120 mg capsule | A presentation being discontinued |
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Propranolol | High blood pressure | 38 labelers | $0.0493 per tablet 20 mg tablet | In shortage |
| Losartan | High blood pressure | 44 labelers | $0.0327 per tablet 50 mg tablet | No current entry |
| Amlodipine | High blood pressure | 42 labelers | $0.0102 per tablet 5 mg tablet | No current entry |
| Clonidine | High blood pressure | 37 labelers | $0.0241 per tablet 0.1 mg tablet | No current entry |
| Valsartan | High blood pressure | 34 labelers | $0.0963 per tablet 40 mg tablet | A presentation being discontinued |
Every medicine labeled for the same conditions as levamlodipine
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to levamlodipine
- 72 medicines for the same use
- Levamlodipine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other